Patient-centric solutions for benign and malignant blood disorder trials

血液学

Work with the experts in the design, conduct and management of hematology trials—from early phase to registrational and post approval.

与我们建立联系

Our experience matters. Advance your hematology therapy with our decades of experience working with large pharma, biotech and research organizations.

Advanced therapeutics expertise. Drive your trial forward with new cell and gene therapies, immuno-oncology drugs and protocols involving bone marrow transplantation.

A team approach. Work with a diverse team to aid in the design and execution of your trial, using our global network of hematologists, oncologists, and trial delivery experts.

Benign and malignant hematology

Fortrea combines scientific expertise with trial design strategists and operational delivery experts in partnership with regulatory and recruitment specialists to craft a complete solution to help accelerate your trials. You can count on our team of more than twenty hematologists with expertise in immuno-oncology therapies, cell and gene therapies and targeted therapeutics such as antibody-drug conjugates.

With recent and relevant experience in benign and malignant hematology trials from early phase to registrational, including acute myeloid leukemia, paroxysmal nocturnal hemoglobinuria, multiple myeloma, thalassemia, non-Hodgkin and B-cell lymphomas, hemophilia and many more, we have the know-how to advance your hematology development needs.

Hematology experience that matters

过去5年来

488

研究

11千+

研究中心

45千+

患者

主要适应症

Acute myeloid leukemia (AML) | Paroxysmal nocturnal hemoglobinuria (PNH) | Multiple myeloma | Hemophilia (A and B) | Thalassemia

Get the latest updates from our hematology team

我们分享我们的最新动态、活动和出版物。

视频

Mobile Clinical Services Hemophilia Case Study. Learn how we kept a pediatric hemophilia patient in their trial.

观看视频

案例研究

Agile partnership in hematological oncology Learn how Fortrea delivered success in parallel complex hematology trials.

查看案例研究

Conference

American Society of Hematology Annual Meeting Join Fortrea at ASH for the latest insights on Hematology trials.

View event

Strategies and solutions that make a difference

Beyond our novel solutions, industry-leading processes and subject matter expertise for your hematology trial, you can:

Enhance site selection and maximize patient recruitment with Xcellerate^®. Utilizing trial data with extensive central laboratory data and other data sources, we help enhance your hematology trial enrollment and retention, which is particularly important for rare hematological indications
Train and qualify sites in your protocol procedures with close collaboration with core and specialty labs

Benefit from adjudication that results in more robust data for DMC/DSMB safety reviews—and no delays to database lock—with Endpoint “fast track strategies”

Delivering hematology leadership